AbCellera Biologics Inc. (ABCL) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Vancouver, BC, 加拿大. 現任CEO為 Carl Hansen.
ABCL 擁有 IPO日期為 2020-12-11, 596 名全職員工, 在 NASDAQ Global Select, 市值為 $1.17B.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
